Is KURA or CGEN more profitable?

Compugen has a net margin of 47.56% compared to Kura Oncology's net margin of -384.30%. Compugen's return on equity of 42.57% beat Kura Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Kura Oncology -384.30% -207.18% -45.17% Compugen 47.56% 42.57% 26.13%

Does the media favor KURA or CGEN?

In the previous week, Kura Oncology had 19 more articles in the media than Compugen. MarketBeat recorded 23 mentions for Kura Oncology and 4 mentions for Compugen. Compugen's average media sentiment score of 1.11 beat Kura Oncology's score of 0.69 indicating that Compugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 6 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Compugen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANNX or CGEN more profitable?

Compugen has a net margin of 47.56% compared to Annexon's net margin of 0.00%. Compugen's return on equity of 42.57% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Compugen 47.56% 42.57% 26.13%

Does the media favor ANNX or CGEN?

In the previous week, Annexon had 17 more articles in the media than Compugen. MarketBeat recorded 21 mentions for Annexon and 4 mentions for Compugen. Compugen's average media sentiment score of 1.11 beat Annexon's score of 0.54 indicating that Compugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 5 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Compugen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DBVT or CGEN more profitable?

Compugen has a net margin of 47.56% compared to DBV Technologies' net margin of -3,506.53%. Compugen's return on equity of 42.57% beat DBV Technologies' return on equity. Company Net Margins Return on Equity Return on Assets DBV Technologies -3,506.53% -119.33% -84.43% Compugen 47.56% 42.57% 26.13%

Does the media prefer DBVT or CGEN?

In the previous week, Compugen had 2 more articles in the media than DBV Technologies. MarketBeat recorded 4 mentions for Compugen and 2 mentions for DBV Technologies. Compugen's average media sentiment score of 1.11 beat DBV Technologies' score of 0.93 indicating that Compugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compugen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACRS or CGEN?

In the previous week, Aclaris Therapeutics had 10 more articles in the media than Compugen. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 4 mentions for Compugen. Compugen's average media sentiment score of 1.11 beat Aclaris Therapeutics' score of 0.07 indicating that Compugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compugen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CGEN or PHAR?

In the previous week, Pharming Group had 4 more articles in the media than Compugen. MarketBeat recorded 8 mentions for Pharming Group and 4 mentions for Compugen. Compugen's average media sentiment score of 1.11 beat Pharming Group's score of 0.46 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Compugen (CGEN) Competitors

$2.41 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.37 -0.04 (-1.87%)

As of 07:34 PM Eastern

Compare

CGEN vs. KURA, ANNX, DBVT, ACRS, and PHAR

Should you buy Compugen stock or one of its competitors? Compugen's main competitors and comparable companies include Kura Oncology (KURA), Annexon (ANNX), DBV Technologies (DBVT), Aclaris Therapeutics (ACRS), and Pharming Group (PHAR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Compugen compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Compugen (NASDAQ:CGEN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Kura Oncology currently has a consensus price target of $25.62, indicating a potential upside of 135.87%. Compugen has a consensus price target of $5.00, indicating a potential upside of 107.47%. Given Kura Oncology's higher probable upside, analysts plainly believe Kura Oncology is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

12.2% of Compugen shares are held by institutional investors. 7.6% of Kura Oncology shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Kura Oncology has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Compugen has a beta of 2.77, meaning that its share price is 177% more volatile than the broader market.

Compugen has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$77.23M	12.48	-$278.67M	-$3.37	N/A
Compugen	$72.76M	3.13	$35.34M	$0.38	6.34

In the previous week, Kura Oncology had 19 more articles in the media than Compugen. MarketBeat recorded 23 mentions for Kura Oncology and 4 mentions for Compugen. Compugen's average media sentiment score of 1.11 beat Kura Oncology's score of 0.69 indicating that Compugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	6 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Compugen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compugen has a net margin of 47.56% compared to Kura Oncology's net margin of -384.30%. Compugen's return on equity of 42.57% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Compugen	47.56%	42.57%	26.13%

Summary

Compugen beats Kura Oncology on 12 of the 17 factors compared between the two stocks.

How does Compugen compare to Annexon?

Annexon (NASDAQ:ANNX) and Compugen (NASDAQ:CGEN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

In the previous week, Annexon had 17 more articles in the media than Compugen. MarketBeat recorded 21 mentions for Annexon and 4 mentions for Compugen. Compugen's average media sentiment score of 1.11 beat Annexon's score of 0.54 indicating that Compugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	5 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Compugen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annexon has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Compugen has a beta of 2.77, indicating that its stock price is 177% more volatile than the broader market.

Compugen has a net margin of 47.56% compared to Annexon's net margin of 0.00%. Compugen's return on equity of 42.57% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Compugen	47.56%	42.57%	26.13%

Annexon currently has a consensus target price of $15.33, suggesting a potential upside of 189.86%. Compugen has a consensus target price of $5.00, suggesting a potential upside of 107.47%. Given Annexon's higher possible upside, analysts clearly believe Annexon is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Compugen has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Compugen	$72.76M	3.13	$35.34M	$0.38	6.34

12.2% of Compugen shares are held by institutional investors. 10.3% of Annexon shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Compugen beats Annexon on 12 of the 16 factors compared between the two stocks.

How does Compugen compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and Compugen (NASDAQ:CGEN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Compugen has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	147.21	-$146.95M	-$3.51	N/A
Compugen	$72.76M	3.13	$35.34M	$0.38	6.34

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by insiders. Comparatively, 9.5% of Compugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Compugen had 2 more articles in the media than DBV Technologies. MarketBeat recorded 4 mentions for Compugen and 2 mentions for DBV Technologies. Compugen's average media sentiment score of 1.11 beat DBV Technologies' score of 0.93 indicating that Compugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compugen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DBV Technologies currently has a consensus price target of $48.50, suggesting a potential upside of 245.93%. Compugen has a consensus price target of $5.00, suggesting a potential upside of 107.47%. Given DBV Technologies' higher possible upside, analysts clearly believe DBV Technologies is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

DBV Technologies has a beta of -0.93, suggesting that its share price is 193% less volatile than the broader market. Comparatively, Compugen has a beta of 2.77, suggesting that its share price is 177% more volatile than the broader market.

Compugen has a net margin of 47.56% compared to DBV Technologies' net margin of -3,506.53%. Compugen's return on equity of 42.57% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Compugen	47.56%	42.57%	26.13%

Summary

Compugen beats DBV Technologies on 12 of the 16 factors compared between the two stocks.

How does Compugen compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Compugen (NASDAQ:CGEN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

In the previous week, Aclaris Therapeutics had 10 more articles in the media than Compugen. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 4 mentions for Compugen. Compugen's average media sentiment score of 1.11 beat Aclaris Therapeutics' score of 0.07 indicating that Compugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compugen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compugen has a net margin of 47.56% compared to Aclaris Therapeutics' net margin of -921.50%. Compugen's return on equity of 42.57% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
Compugen	47.56%	42.57%	26.13%

Aclaris Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Compugen has a beta of 2.77, suggesting that its stock price is 177% more volatile than the broader market.

Compugen has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	103.21	-$64.92M	-$0.58	N/A
Compugen	$72.76M	3.13	$35.34M	$0.38	6.34

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aclaris Therapeutics presently has a consensus target price of $11.50, indicating a potential upside of 98.96%. Compugen has a consensus target price of $5.00, indicating a potential upside of 107.47%. Given Compugen's higher possible upside, analysts clearly believe Compugen is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Compugen beats Aclaris Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Compugen compare to Pharming Group?

Compugen (NASDAQ:CGEN) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Compugen has a net margin of 47.56% compared to Pharming Group's net margin of 2.51%. Compugen's return on equity of 42.57% beat Pharming Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.56%	42.57%	26.13%
Pharming Group	2.51%	3.40%	1.90%

Compugen has higher earnings, but lower revenue than Pharming Group. Compugen is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	3.13	$35.34M	$0.38	6.34
Pharming Group	$376.13M	2.21	$2.85M	$0.12	97.67

Compugen has a beta of 2.77, meaning that its share price is 177% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

Compugen presently has a consensus price target of $5.00, indicating a potential upside of 107.47%. Pharming Group has a consensus price target of $38.67, indicating a potential upside of 229.92%. Given Pharming Group's higher possible upside, analysts clearly believe Pharming Group is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Pharming Group had 4 more articles in the media than Compugen. MarketBeat recorded 8 mentions for Pharming Group and 4 mentions for Compugen. Compugen's average media sentiment score of 1.11 beat Pharming Group's score of 0.46 indicating that Compugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

12.2% of Compugen shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Compugen beats Pharming Group on 12 of the 16 factors compared between the two stocks.

Get Compugen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEN vs. The Competition

Export

Metric	Compugen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$227.87M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	6.34	10.67	269.06	25.28
Price / Sales	3.13	1,294.08	602.43	91.76
Price / Cash	6.45	102.88	70.48	50.90
Price / Book	2.56	16.78	12.91	6.24
Net Income	$35.34M	-$13.32M	$3.45B	$347.60M
7 Day Performance	N/A	1.74%	1.12%	1.07%
1 Month Performance	4.78%	1.60%	1.79%	1.03%
1 Year Performance	66.21%	56.43%	67.69%	20.77%

Compugen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEN Compugen	4.2568 of 5 stars	$2.41 flat	$5.00 +107.5%	+62.8%	$227.87M	$72.76M	6.34	70	Positive News
KURA Kura Oncology	2.948 of 5 stars	$9.88 +0.3%	$25.46 +157.7%	+55.5%	$877.05M	$67.48M	N/A	130	Trending News Earnings Report Analyst Forecast Analyst Revision
ANNX Annexon	3.3085 of 5 stars	$5.30 -1.8%	$15.33 +189.6%	+102.3%	$865.89M	N/A	N/A	60	Earnings Report Analyst Upgrade Options Volume
DBVT DBV Technologies	2.9012 of 5 stars	$14.29 +0.1%	$48.50 +239.4%	+41.6%	$845.96M	$5.64M	N/A	80
ACRS Aclaris Therapeutics	2.0704 of 5 stars	$5.87 -0.6%	$11.50 +96.1%	+244.7%	$820.04M	$7.83M	N/A	100	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEN) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compugen (CGEN) Competitors

CGEN vs. KURA, ANNX, DBVT, ACRS, and PHAR

How does Compugen compare to Kura Oncology?

Summary

How does Compugen compare to Annexon?

Summary

How does Compugen compare to DBV Technologies?

Summary

How does Compugen compare to Aclaris Therapeutics?

Summary

How does Compugen compare to Pharming Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN vs. The Competition

Compugen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compugen (CGEN) Competitors

CGEN vs. KURA, ANNX, DBVT, ACRS, and PHAR

How does Compugen compare to Kura Oncology?

Do analysts prefer KURA or CGEN?

Do institutionals and insiders hold more shares of KURA or CGEN?

Which has more volatility and risk, KURA or CGEN?

Which has better earnings & valuation, KURA or CGEN?

Does the media favor KURA or CGEN?

Is KURA or CGEN more profitable?

Summary

How does Compugen compare to Annexon?

Does the media favor ANNX or CGEN?

Which has more risk & volatility, ANNX or CGEN?

Is ANNX or CGEN more profitable?

Do analysts recommend ANNX or CGEN?

Which has preferable earnings & valuation, ANNX or CGEN?

Do institutionals and insiders hold more shares of ANNX or CGEN?

Summary

How does Compugen compare to DBV Technologies?

Which has preferable valuation and earnings, DBVT or CGEN?

Do insiders and institutionals hold more shares of DBVT or CGEN?

Does the media prefer DBVT or CGEN?

Do analysts rate DBVT or CGEN?

Which has more risk & volatility, DBVT or CGEN?

Is DBVT or CGEN more profitable?

Summary

How does Compugen compare to Aclaris Therapeutics?

Does the media favor ACRS or CGEN?

Is ACRS or CGEN more profitable?

Which has more risk and volatility, ACRS or CGEN?

Which has better earnings and valuation, ACRS or CGEN?

Do institutionals and insiders believe in ACRS or CGEN?

Do analysts rate ACRS or CGEN?

Summary

How does Compugen compare to Pharming Group?

Is CGEN or PHAR more profitable?

Which has preferable valuation & earnings, CGEN or PHAR?

Which has more volatility & risk, CGEN or PHAR?

Do analysts recommend CGEN or PHAR?

Does the media favor CGEN or PHAR?

Do insiders & institutionals believe in CGEN or PHAR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN vs. The Competition

Compugen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools